Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
- Covino brings global biopharmaceutical finance experience to
Novavax John Trizzino, Chief Business Officer, takes on additional role as Chief Commercial Officer Filip Dubovsky, M.D. promoted to Executive Vice President, Chief Medical Officer Biegie Leepromoted to Senior Vice President, Chief Information Officer
“We welcome Greg’s multifaceted and extensive global financial experience at a pivotal time as
Prior to joining
“I look forward to contributing to Novavax’ positive impact on reducing the global burden of serious infectious diseases around the world, including COVID-19 and influenza,” said
Chief Medical Officer,
“I congratulate John on his expanded responsibilities, and Filip and Biegie on their promotions, as
NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the
NanoFlu™ is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains Novavax’ patented saponin-based Matrix-M™ adjuvant.
Erika Trahanir@novavax.com 240-268-2022 Media Brandzone/KOGS Communication Edna Kaplankaplan@kogspr.com 617-974-8659
Source: Novavax, Inc.